molsidomine has been researched along with Heart Failure in 61 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the mechanisms involved in nitrate tolerance, we randomized 23 patients with congestive heart failure resulting from coronary artery disease to an isosorbide dinitrate or a molsidomine infusion." | 9.07 | Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. ( Berkenboom, G; de Cannière, D; Staroukine, M; Unger, P; Vachiery, JL, 1994) |
| "The effect of vasodilator Molsidomine (M) vs placebo on left ventricular dimensions and function measured by echocardiography was evaluated in a randomized study on 23 patients (pts) with refractory congestive heart failure (R CF) (NYHA class III-IV)." | 9.06 | [Effect of the acute administration of molsidomine in refractory congestive heart failure. A double-blind randomized non-invasive study]. ( Bordi, L; Carunchio, A; Coletta, C; Fera, MS; Galati, A; Salustri, A, 1986) |
| "Molsidomine, one of the sydnonimine group of drugs; the object of this study was to evaluate its efforts in refractory cardiac failure." | 9.05 | [Long-term clinical and hemodynamic results of the treatment of refractory cardiac failure with molsidomine]. ( Acar, J; Escudier, B; Hannachi, N; Kolski, H; Kulas, A; Witchitz, S, 1984) |
| "The effects of molsidomine were studied in seven patients with refractory congestive heart failure by means of two-dimensional echocardiography." | 9.05 | Effects of molsidomine on left ventricular dimensions and cardiac function in patients with chronic heart failure. ( Berkenboom, GM; Degre, SG; Sobolski, JC; Stoupel, EE; Vandermoten, PP, 1985) |
| "The effect of molsidomine on hemodynamic properties was studied in 10 patients with chronic congestive heart failure in New York Heart Association functional classes III and IV." | 9.05 | The influence of molsidomine on the hemodynamics of patients with chronic heart failure at rest and during exercise. ( Kahle, T; Larbig, DT; Milstrey, HR; Nasse, H, 1985) |
| "In this report we describe the clinical and hemodynamic response of refractory cardiac failure to molsidomine." | 9.05 | Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure. ( Acar, J; Escudier, B; Kulas, A, 1985) |
| "The aim of the study was to estimate the influence of long-term treatment with molsidomine on structure, systolic function and neurohormonal parameters in patients with chronic heart failure (CHF)." | 7.70 | [The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors]. ( Jołda-Mydłowska, B; Kosmala, W; Spring, A; Witkowska, M, 1998) |
| " In 13 out of 16 patients (5 women, 11 men, 62 [53/71] years [median, 25%/75%-percentiles]) with chronic heart failure (NYHA stage II-III; median angiographic ejection fraction (EF) 55%) and coronary artery disease (stenosis of at least 75%) the development of tolerance under the continuous infusion of high doses of nitroglycerin (10 mg/h) was observed." | 7.68 | [Hemodynamic effect of molsidomine in coronary patients with heart failure with clinically manifest nitrate tolerance]. ( Bodemann, T; Danne, O; Eichstädt, H; Hochrein, H; Möckel, M; Müller, R; Piske, G; Störk, S; Störk, T, 1993) |
| "Haemodynamic monitoring, using a Swan-Ganz balloon catheter, was done in 14 patients with pump failure associated with acute myocardial infarction, before and for 8 h after single 6 mg oral dose of molsidomine." | 7.67 | Haemodynamic effects of oral molsidomine in pump failure complicating myocardial infarction. ( Cercós, H; Cohn, JL; Drajer, S; Faerman, G; Nijensohn, CM; Romero, N; Soifer, S; Torres, H; Vazquez, A, 1984) |
| "Acute haemodynamic effects of molsidomine, antianginal drug with vasodilator properties, were evaluated in 12 male patients with chronic congestive heart failure in New York Heart Association functional class 3 or 4 (mean age 56 +/- 7 years; ischemic heart disease in 8 cases, dilated cardiomyopathy in 3 cases, heart disease of combined aetiology in 1 case)." | 7.67 | [Hemodynamic effects of molsidomine in chronic congestive heart failure]. ( Camerini, F; Humar, F; Maras, P; Musitelli, G, 1986) |
| "The short-term hemodynamic effects of molsidomine (4 mg sublingually) were evaluated in 13 patients with congestive heart failure following acute myocardial infarction." | 7.67 | Hemodynamic effects of molsidomine in patients with heart failure following acute myocardial infarction. ( Bracchetti, D; Brunelli, A; Cantelli, I; Lolli, C, 1985) |
| "We studied the effects of molsidomine on hemodynamic properties and blood gas levels in eight patients with acute myocardial infarction and left heart failure." | 7.67 | Effects of molsidomine on hemodynamics and blood gases in acute myocardial infarction with left heart failure. ( Bernard, R; Friart, A; Jacobs, P; Liebens, I; Renard, M, 1985) |
| "The unloading mechanisms and side of peripheral action of the new antianginal drug molsidomine was compared with isosorbide dinitrate (ISDN) in 14 patients with acute myocardial infarction using a Swan-Ganz catheter and venous occlusion plethysmography." | 7.66 | Unloading effects of molsidomine on peripheral circulation and cardiac hemodynamics in patients with acute myocardial infarction. ( Hayakawa, H; Kimura, E; Obayashi, K; Rose, HB; Seino, Y; Takano, T; Vyden, JK, 1983) |
| "The use of nitrates for treatment of heart failure is encumbered by tolerance, caused by whatever mechanism, which has been reported only in a few instances with sydnonimines." | 6.69 | Infusions with molsidomine and isosorbide-5-mononitrate in congestive heart failure: mechanisms underlying attenuation of effects. ( Beyerle, A; Hähnel, I; Lampen, M; Lehmann, G; Reiniger, G; Schömig, A, 1998) |
| "Patients suffering from congestive heart failure combined with gastrointestinal congestion often present irregular resorption and metabolism of orally applicated cardiovascular drugs." | 6.67 | [Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?]. ( Grosse-Heitmeyer, W; Huber, T; Ostrowski, J, 1993) |
| "In patients with congestive heart failure, 1 hour after administration of 4 mg of molsidomine there were significant reductions in systolic and diastolic pulmonary artery pressures of 25% and 30%, respectively." | 6.66 | Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure. ( Dirschinger, J; Rudolph, W, 1985) |
| "Molsidomine was unable to significantly attenuate mortality, development of heart failure and morphological damage induced by DAU." | 5.43 | Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? ( Adamcová, M; Bureš, J; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Kovaříková, P; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Reimerová, P; Šimůnek, T; Štěrba, M; Vostatková, L, 2016) |
| " The long-term use of the peripheral vasodilator molsidomin effectively prevents heart failure in myocardial infarction survivors." | 5.27 | [Comparative efficacy of the long-term use of long-acting nitroglycerin (sustak) and molsidomine after myocardial infarct complicated by heart failure]. ( Dormidontov, EN; Petrov, DV, 1986) |
| "To evaluate the mechanisms involved in nitrate tolerance, we randomized 23 patients with congestive heart failure resulting from coronary artery disease to an isosorbide dinitrate or a molsidomine infusion." | 5.07 | Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. ( Berkenboom, G; de Cannière, D; Staroukine, M; Unger, P; Vachiery, JL, 1994) |
| "To assess the hemodynamic effects of SIN-1, the active metabolite of the venodilator molsidomine, after acute as well as chronic intravenous administration, ten patients with exacerbation of chronic heart failure were studied." | 5.06 | Hemodynamic effects of SIN-1 in acute left heart failure. ( Degre, S; Depelchin, P; Ibrahim, TM; Jottrand, M; Sobolski, J; Unger, PH, 1989) |
| "The effect of vasodilator Molsidomine (M) vs placebo on left ventricular dimensions and function measured by echocardiography was evaluated in a randomized study on 23 patients (pts) with refractory congestive heart failure (R CF) (NYHA class III-IV)." | 5.06 | [Effect of the acute administration of molsidomine in refractory congestive heart failure. A double-blind randomized non-invasive study]. ( Bordi, L; Carunchio, A; Coletta, C; Fera, MS; Galati, A; Salustri, A, 1986) |
| " Cyclo-ergometric tests were used to evaluate the antianginal effects of molsidomine compared with a placebo administered to 5 ambulatory patients with stable angina pectoris." | 5.05 | The antianginal effect of molsidomine in prolonged oral therapy. A double blind, crossover, randomized study. ( Baudry, C, 1982) |
| "Molsidomine, one of the sydnonimine group of drugs; the object of this study was to evaluate its efforts in refractory cardiac failure." | 5.05 | [Long-term clinical and hemodynamic results of the treatment of refractory cardiac failure with molsidomine]. ( Acar, J; Escudier, B; Hannachi, N; Kolski, H; Kulas, A; Witchitz, S, 1984) |
| "The effects of molsidomine were studied in seven patients with refractory congestive heart failure by means of two-dimensional echocardiography." | 5.05 | Effects of molsidomine on left ventricular dimensions and cardiac function in patients with chronic heart failure. ( Berkenboom, GM; Degre, SG; Sobolski, JC; Stoupel, EE; Vandermoten, PP, 1985) |
| "The effect of molsidomine on hemodynamic properties was studied in 10 patients with chronic congestive heart failure in New York Heart Association functional classes III and IV." | 5.05 | The influence of molsidomine on the hemodynamics of patients with chronic heart failure at rest and during exercise. ( Kahle, T; Larbig, DT; Milstrey, HR; Nasse, H, 1985) |
| "In this report we describe the clinical and hemodynamic response of refractory cardiac failure to molsidomine." | 5.05 | Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure. ( Acar, J; Escudier, B; Kulas, A, 1985) |
| "Organic nitrates still are one of the most important drug classes used in the treatment of an acute coronary syndrome and stable coronary artery disease as well as acute and chronic congestive heart failure." | 4.84 | [Recent findings on nitrates: their action, bioactivation and development of tolerance]. ( Münzel, T, 2008) |
| "The aim of the study was to estimate the influence of long-term treatment with molsidomine on structure, systolic function and neurohormonal parameters in patients with chronic heart failure (CHF)." | 3.70 | [The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors]. ( Jołda-Mydłowska, B; Kosmala, W; Spring, A; Witkowska, M, 1998) |
| " In 13 out of 16 patients (5 women, 11 men, 62 [53/71] years [median, 25%/75%-percentiles]) with chronic heart failure (NYHA stage II-III; median angiographic ejection fraction (EF) 55%) and coronary artery disease (stenosis of at least 75%) the development of tolerance under the continuous infusion of high doses of nitroglycerin (10 mg/h) was observed." | 3.68 | [Hemodynamic effect of molsidomine in coronary patients with heart failure with clinically manifest nitrate tolerance]. ( Bodemann, T; Danne, O; Eichstädt, H; Hochrein, H; Möckel, M; Müller, R; Piske, G; Störk, S; Störk, T, 1993) |
| "Haemodynamic monitoring, using a Swan-Ganz balloon catheter, was done in 14 patients with pump failure associated with acute myocardial infarction, before and for 8 h after single 6 mg oral dose of molsidomine." | 3.67 | Haemodynamic effects of oral molsidomine in pump failure complicating myocardial infarction. ( Cercós, H; Cohn, JL; Drajer, S; Faerman, G; Nijensohn, CM; Romero, N; Soifer, S; Torres, H; Vazquez, A, 1984) |
| "The short-term hemodynamic effects of molsidomine (4 mg sublingually) were evaluated in 13 patients with congestive heart failure following acute myocardial infarction." | 3.67 | Hemodynamic effects of molsidomine in patients with heart failure following acute myocardial infarction. ( Bracchetti, D; Brunelli, A; Cantelli, I; Lolli, C, 1985) |
| "Hemodynamic effects of vasodilator agents (molsidomine, nitroglycerin, isosorbide dinitrate or prostaglandin I2) were studied in 53 patients with acute myocardial infarction." | 3.67 | Hemodynamic and metabolic effects of vasodilator therapy for heart failure in acute myocardial infarction. ( Kodama, K; Koretsune, Y; Nanto, S; Taniura, K, 1984) |
| "Acute haemodynamic effects of molsidomine, antianginal drug with vasodilator properties, were evaluated in 12 male patients with chronic congestive heart failure in New York Heart Association functional class 3 or 4 (mean age 56 +/- 7 years; ischemic heart disease in 8 cases, dilated cardiomyopathy in 3 cases, heart disease of combined aetiology in 1 case)." | 3.67 | [Hemodynamic effects of molsidomine in chronic congestive heart failure]. ( Camerini, F; Humar, F; Maras, P; Musitelli, G, 1986) |
| "We studied the effects of molsidomine on hemodynamic properties and blood gas levels in eight patients with acute myocardial infarction and left heart failure." | 3.67 | Effects of molsidomine on hemodynamics and blood gases in acute myocardial infarction with left heart failure. ( Bernard, R; Friart, A; Jacobs, P; Liebens, I; Renard, M, 1985) |
| "We have used equilibrium gated blood pool scintigraphy to evaluate the hemodynamic effects and duration of action of molsidomine, a new peripheral vasodilator antianginal drug, after sublingual administration (4 mg) in five patients with heart failure." | 3.67 | Evaluation of the effects of molsidomine by cardiac equilibrium blood pool scintigraphy. ( Chevigné, M; Kassab, A; Kulbertus, H; Rigo, P, 1985) |
| "The unloading mechanisms and side of peripheral action of the new antianginal drug molsidomine was compared with isosorbide dinitrate (ISDN) in 14 patients with acute myocardial infarction using a Swan-Ganz catheter and venous occlusion plethysmography." | 3.66 | Unloading effects of molsidomine on peripheral circulation and cardiac hemodynamics in patients with acute myocardial infarction. ( Hayakawa, H; Kimura, E; Obayashi, K; Rose, HB; Seino, Y; Takano, T; Vyden, JK, 1983) |
| "The use of nitrates for treatment of heart failure is encumbered by tolerance, caused by whatever mechanism, which has been reported only in a few instances with sydnonimines." | 2.69 | Infusions with molsidomine and isosorbide-5-mononitrate in congestive heart failure: mechanisms underlying attenuation of effects. ( Beyerle, A; Hähnel, I; Lampen, M; Lehmann, G; Reiniger, G; Schömig, A, 1998) |
| "Patients suffering from congestive heart failure combined with gastrointestinal congestion often present irregular resorption and metabolism of orally applicated cardiovascular drugs." | 2.67 | [Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?]. ( Grosse-Heitmeyer, W; Huber, T; Ostrowski, J, 1993) |
| "In patients with congestive heart failure, 1 hour after administration of 4 mg of molsidomine there were significant reductions in systolic and diastolic pulmonary artery pressures of 25% and 30%, respectively." | 2.66 | Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure. ( Dirschinger, J; Rudolph, W, 1985) |
| "Molsidomine was unable to significantly attenuate mortality, development of heart failure and morphological damage induced by DAU." | 1.43 | Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? ( Adamcová, M; Bureš, J; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Kovaříková, P; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Reimerová, P; Šimůnek, T; Štěrba, M; Vostatková, L, 2016) |
| " The differences between aorto-caval fistula rats and sham operated rats were probably the result of increased basal EDRF-NO release in the former, since NO synthase blockade abolished the differences in both aortic cGMP and the dose-response curve to Sin-1." | 1.29 | Vascular relaxation and cyclic guanosine monophosphate in a rat model of high output heart failure. ( Arnal, JF; Michel, JB; Schott, C; Stoclet, JC, 1993) |
| "Molsidomine (M) is a recent nitrates-like drug acting for a longer time than the classical nitrates." | 1.28 | Acute effect of molsidomine on pulmonary circulation of patients with chronic obstructive pulmonary disease. ( Frans, A; Lampert, E; Mwepu, AK, 1989) |
| "Corvaton treatment of 23 patients with congestive heart failure caused by rheumatic valvular heart diseases, continued for 10 mos." | 1.27 | [Efficacy of corvaton in the long-term ambulatory treatment of heart failure in patients with rheumatic heart lesions]. ( Koshlia, VI, 1986) |
| " The long-term use of the peripheral vasodilator molsidomin effectively prevents heart failure in myocardial infarction survivors." | 1.27 | [Comparative efficacy of the long-term use of long-acting nitroglycerin (sustak) and molsidomine after myocardial infarct complicated by heart failure]. ( Dormidontov, EN; Petrov, DV, 1986) |
| " Trinitrin and its derivatives occupy an intermediate position because of their relatively low bioavailability after oral administration: long-term administration is not always easy and may require special modes of administration (i." | 1.27 | [Classification and principles of the use of vasodilators in the treatment of left ventricular insufficiency]. ( Cattan, S; Degeorges, M; Guérin, F; Pailleret, JJ; Weber, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (60.66) | 18.7374 |
| 1990's | 22 (36.07) | 18.2507 |
| 2000's | 1 (1.64) | 29.6817 |
| 2010's | 1 (1.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lenčová-Popelová, O | 1 |
| Jansová, H | 1 |
| Jirkovský, E | 1 |
| Bureš, J | 1 |
| Jirkovská-Vávrová, A | 1 |
| Mazurová, Y | 1 |
| Reimerová, P | 1 |
| Vostatková, L | 1 |
| Adamcová, M | 1 |
| Hroch, M | 1 |
| Pokorná, Z | 1 |
| Kovaříková, P | 1 |
| Šimůnek, T | 1 |
| Štěrba, M | 1 |
| Münzel, T | 2 |
| Otero, F | 1 |
| Fernández Berges, DJ | 1 |
| Milei, J | 1 |
| Agejas, R | 1 |
| Vázquez, A | 2 |
| Pautasso, E | 1 |
| Rigaud, M | 1 |
| Luwaert, R | 1 |
| Jouret, G | 1 |
| Bardet, J | 1 |
| Bourdarias, JP | 1 |
| Kulas, A | 2 |
| Escudier, B | 2 |
| Hannachi, N | 1 |
| Kolski, H | 1 |
| Witchitz, S | 1 |
| Acar, J | 2 |
| Kodama, K | 1 |
| Koretsune, Y | 1 |
| Nanto, S | 1 |
| Taniura, K | 1 |
| Sokolov, AM | 2 |
| Suloeva, MN | 1 |
| Drajer, S | 1 |
| Cercós, H | 1 |
| Torres, H | 1 |
| Cohn, JL | 1 |
| Romero, N | 1 |
| Faerman, G | 1 |
| Soifer, S | 1 |
| Nijensohn, CM | 1 |
| Seino, Y | 1 |
| Vyden, JK | 1 |
| Rose, HB | 1 |
| Takano, T | 1 |
| Obayashi, K | 1 |
| Hayakawa, H | 1 |
| Kimura, E | 1 |
| Mukharliamov, NM | 1 |
| Babalis, D | 1 |
| Levy, B | 1 |
| Azancot, I | 1 |
| Georgiopoulos, G | 1 |
| Beaufils, P | 1 |
| Slama, R | 1 |
| Hayasaki, K | 1 |
| Tokunaga, M | 1 |
| Kodama, H | 1 |
| Kikuchi, H | 1 |
| Matsunaga, K | 1 |
| Ogata, A | 1 |
| Ogawa, T | 1 |
| Hoffmann, E | 1 |
| Traina, M | 1 |
| Alfano, R | 1 |
| Piraino, GL | 1 |
| Raineri, A | 1 |
| Baudry, C | 1 |
| Charchoglian, RA | 1 |
| Esin, NN | 1 |
| Belozerov, GE | 1 |
| Körner, A | 1 |
| Ol'binskaia, LI | 2 |
| Sizova, ZhM | 2 |
| Morozov, IuA | 1 |
| Lehmann, G | 3 |
| Reiniger, G | 2 |
| Beyerle, A | 3 |
| Zeitler, H | 1 |
| Rudolph, W | 4 |
| Krüger, R | 2 |
| Grewe, R | 2 |
| Kasper, W | 1 |
| Just, H | 1 |
| Störk, T | 3 |
| Möckel, M | 3 |
| Danne, O | 3 |
| Müller, R | 3 |
| Eichstädt, H | 3 |
| Hochrein, H | 3 |
| Grosse-Heitmeyer, W | 3 |
| Huber, T | 3 |
| Jahed, MM | 1 |
| Alekperov, EE | 1 |
| Unger, P | 1 |
| Vachiery, JL | 1 |
| de Cannière, D | 1 |
| Staroukine, M | 1 |
| Berkenboom, G | 1 |
| Arnal, JF | 1 |
| Schott, C | 1 |
| Stoclet, JC | 1 |
| Michel, JB | 1 |
| Störk, S | 1 |
| Piske, G | 1 |
| Bodemann, T | 1 |
| Ostrowski, J | 1 |
| Blasini, R | 1 |
| Schömig, A | 2 |
| Hähnel, I | 1 |
| Lampen, M | 1 |
| Spring, A | 1 |
| Jołda-Mydłowska, B | 1 |
| Kosmala, W | 1 |
| Witkowska, M | 1 |
| Rietbrock, S | 1 |
| Harder, S | 1 |
| Dirschinger, J | 2 |
| Butorov, IV | 1 |
| Matkovskiĭ, SK | 1 |
| Butorova, VG | 1 |
| Caralis, DG | 1 |
| Kyriakides, Z | 1 |
| Ioakimides, C | 1 |
| Khrustalev, OA | 1 |
| Berkovskiĭ, ML | 1 |
| Degtiarev, OA | 1 |
| Ivanov, AI | 1 |
| Sotskova, TV | 1 |
| Mikerova, TM | 1 |
| Ibrahim, TM | 1 |
| Unger, PH | 1 |
| Sobolski, J | 1 |
| Depelchin, P | 1 |
| Jottrand, M | 1 |
| Degre, S | 1 |
| Mwepu, AK | 1 |
| Lampert, E | 1 |
| Frans, A | 1 |
| Bondarenko, IP | 1 |
| Tkachev, VA | 1 |
| Vorob'ev, LP | 1 |
| Kaziulin, AN | 1 |
| Renard, M | 2 |
| Verhoeven, A | 1 |
| Liebens, I | 2 |
| Bernard, R | 2 |
| Dormidontov, EN | 1 |
| Petrov, DV | 1 |
| Daskalov, TR | 1 |
| Coletta, C | 1 |
| Galati, A | 1 |
| Carunchio, A | 1 |
| Salustri, A | 1 |
| Bordi, L | 1 |
| Fera, MS | 1 |
| Humar, F | 1 |
| Maras, P | 1 |
| Musitelli, G | 1 |
| Camerini, F | 1 |
| Koshlia, VI | 2 |
| Chevigné, M | 1 |
| Rigo, P | 1 |
| Kassab, A | 1 |
| Kulbertus, H | 1 |
| Berkenboom, GM | 1 |
| Sobolski, JC | 1 |
| Vandermoten, PP | 1 |
| Stoupel, EE | 1 |
| Degre, SG | 1 |
| Cantelli, I | 1 |
| Lolli, C | 1 |
| Brunelli, A | 1 |
| Bracchetti, D | 1 |
| Mirrakhimov, MM | 1 |
| Moldotashev, IK | 1 |
| Kadraliev, KK | 1 |
| Larbig, DT | 1 |
| Milstrey, HR | 1 |
| Nasse, H | 1 |
| Kahle, T | 1 |
| Jacobs, P | 1 |
| Friart, A | 1 |
| Weber, S | 1 |
| Pailleret, JJ | 1 |
| Cattan, S | 1 |
| Guérin, F | 1 |
| Degeorges, M | 1 |
4 reviews available for molsidomine and Heart Failure
| Article | Year |
|---|---|
[Recent findings on nitrates: their action, bioactivation and development of tolerance].
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Coronary Disease; Drug Tolerance; End | 2008 |
[Nitric oxide donors in therapy of chronic heart failure].
Topics: Chronic Disease; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Molsidomine; Nitrates; Nitric | 1997 |
Clinical comparison of nitrates and sydnonimines.
Topics: Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; He | 1991 |
[Drug treatment of patients with the chronic form of atrial fibrillation in counterindications for cardioversion (a review)].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anabolic Agents; Atrial Fibrillation; Calcium Channel Block | 1985 |
15 trials available for molsidomine and Heart Failure
| Article | Year |
|---|---|
[Long-term clinical and hemodynamic results of the treatment of refractory cardiac failure with molsidomine].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Heart Failure | 1984 |
The antianginal effect of molsidomine in prolonged oral therapy. A double blind, crossover, randomized study.
Topics: Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Heart Failure | 1982 |
[Clinical study of the preparation korvatone].
Topics: Clinical Trials as Topic; Female; Heart Aneurysm; Heart Failure; Hemodynamics; Humans; Male; Middle | 1982 |
Haemodynamic evaluation of two regimens of molsidomine in patients with chronic congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Drug Delivery Systems; Heart Failure; Hemodynamic | 1995 |
[Comparison of oral and intravenous administration of molsidomine in patients with heart failure].
Topics: Administration, Oral; Adult; Aged; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intraveno | 1994 |
Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure.
Topics: Biotransformation; Double-Blind Method; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Isosorb | 1994 |
[Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?].
Topics: Administration, Oral; Adult; Aged; Female; Heart Failure; Humans; Hypertension, Portal; Infusions, I | 1993 |
Infusions with molsidomine and isosorbide-5-mononitrate in congestive heart failure: mechanisms underlying attenuation of effects.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Double-Blind Method; Drug Tolerance; Female; Fluid Shifts; | 1998 |
Hemodynamic effects of SIN-1 in acute left heart failure.
Topics: Aged; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intr | 1989 |
[Treatment of stress-induced angina pectoris and chronic heart failure with molsidomine].
Topics: Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Exercise Test; Hea | 1986 |
[Effect of the acute administration of molsidomine in refractory congestive heart failure. A double-blind randomized non-invasive study].
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Drug Evaluation; Echocardiography; Female; Heart F | 1986 |
Effects of molsidomine on left ventricular dimensions and cardiac function in patients with chronic heart failure.
Topics: Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Male; Molsidomine; Myocardial Con | 1985 |
Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure.
Topics: Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Electrocard | 1985 |
The influence of molsidomine on the hemodynamics of patients with chronic heart failure at rest and during exercise.
Topics: Blood Pressure; Cardiac Output; Clinical Trials as Topic; Exercise Test; Female; Heart Failure; Hemo | 1985 |
Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Male; Mi | 1985 |
42 other studies available for molsidomine and Heart Failure
| Article | Year |
|---|---|
Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Cell Line, | 2016 |
Hemodynamic changes produced by molsidomine in patients with congestive myocardiopathy.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiomyopathy, Dilated; Female; Heart Failure; Heart Rate; | 1984 |
[Hemodynamic effects of sublingual molsidomine in patients with or without cardiac failure].
Topics: Adult; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Molsidomine; Mouth Floor; Nitroglycer | 1983 |
Hemodynamic and metabolic effects of vasodilator therapy for heart failure in acute myocardial infarction.
Topics: Blood Pressure; Cardiac Output; Coronary Circulation; Epoprostenol; Female; Heart Failure; Heart Rat | 1984 |
[Effect of korvatone on the hemodynamic indices of rheumatism patients].
Topics: Adult; Aged; Chronic Disease; Drug Evaluation; Heart Failure; Hemodynamics; Humans; Middle Aged; Mol | 1984 |
Haemodynamic effects of oral molsidomine in pump failure complicating myocardial infarction.
Topics: Aged; Antihypertensive Agents; Cardiac Catheterization; Cardiac Output; Female; Heart Failure; Hemod | 1984 |
Unloading effects of molsidomine on peripheral circulation and cardiac hemodynamics in patients with acute myocardial infarction.
Topics: Adult; Aged; Blood Circulation; Blood Flow Velocity; Central Venous Pressure; Female; Heart Failure; | 1983 |
[Peripheral vasodilators in the treatment of cardiac insufficiency].
Topics: Heart Failure; Humans; Infusions, Parenteral; Molsidomine; Morpholines; Nitroglycerin; Nitroprusside | 1981 |
[Effect of nitroglycerin and N-ethoxycarbonyl-3-morpholinosydnonomine on the walls of large arteries].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Heart Failure; Humans; Male; Middle Aged; Mols | 1982 |
[Effects of molsidomine on hemodynamics for the patients with chronic heart failure (author's transl)].
Topics: Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Molsidomine; | 1981 |
[Hemodynamic effects of molsidomine in chronic cardiac decompensation].
Topics: Aged; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Molsidomine; Oxadiazoles; S | 1981 |
[The physicochemical properties of molsidomine preparations and their efficacy in treating IHD and circulatory failure].
Topics: Chemical Phenomena; Chemistry, Physical; Drug Evaluation; Female; Heart Failure; Hemodynamics; Human | 1995 |
[The hemodynamic effectiveness of molsidomine infusions in patients with acute coronary insufficiency].
Topics: Aged; Angina, Unstable; Cardiac Output; Dose-Response Relationship, Drug; Drug Administration Schedu | 1994 |
[Continuous molsidomine infusions in patients with unstable angina pectoris and acute myocardial infarct].
Topics: Adult; Aged; Angina, Unstable; Dose-Response Relationship, Drug; Drug Administration Schedule; Femal | 1994 |
[Intravenous molsidomine administration in heart failure. Part I: Dose-response relationship with reference to hemodynamic parameters].
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Hemodyn | 1994 |
[Intravenous molsidomine administration in heart failure. Part II: Comparison with nitroglycerin and effectiveness in nitrate tolerance].
Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Heart Fai | 1994 |
[Acute hemodynamic effects of intravenous administration of molsidomine in secondary pulmonary hypertension and right heart failure].
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Hemodyn | 1994 |
[The effect of molsidomine preparations on the coronary and myocardial reserves of patients with IHD complicated by circulatory failure].
Topics: Coronary Circulation; Drug Evaluation; Female; Heart; Heart Failure; Hemodynamics; Humans; Male; Mid | 1994 |
Vascular relaxation and cyclic guanosine monophosphate in a rat model of high output heart failure.
Topics: Acetylcholine; Animals; Atrial Natriuretic Factor; Calcimycin; Cyclic GMP; Disease Models, Animal; D | 1993 |
[Hemodynamic effect of molsidomine in coronary patients with heart failure with clinically manifest nitrate tolerance].
Topics: Aged; Coronary Disease; Drug Therapy, Combination; Drug Tolerance; Female; Heart Failure; Hemodynami | 1993 |
[The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Digoxin; Diuretics; Electrocardiogr | 1998 |
Pharmacokinetics and pharmacodynamics of molsidomine in patients with liver dysfunction due to congestive heart failure.
Topics: Adult; Aged; Biological Availability; Biotransformation; Central Venous Pressure; Female; Half-Life; | 1992 |
[The role of peripheral vasodilators in the treatment of congestive heart failure in chronic cor pulmonale].
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Molsidomine; Nitrog | 1991 |
Acute hemodynamic effects of molsidomine in patients with ischemic cardiomyopathy.
Topics: Adult; Aged; Coronary Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Molsi | 1991 |
[Use of peripheral vasodilator agents corbaton and corinfar combined with digoxin in patients with congestive heart failure of rheumatic etiology].
Topics: Adult; Digoxin; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Male; Middle | 1990 |
[Nifedipine and molsidomine treatment of circulatory insufficiency in elderly patients with hypertension].
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Glycosides; Diuretics; Drug Evaluation; Drug Therapy, | 1990 |
Acute effect of molsidomine on pulmonary circulation of patients with chronic obstructive pulmonary disease.
Topics: Heart Failure; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Molsi | 1989 |
[The effectiveness of digoxin and sidnofarm in the initial stages of chronic circulatory failure].
Topics: Angina Pectoris; Chronic Disease; Digoxin; Drug Evaluation; Female; Heart Failure; Hemodynamics; Hum | 1989 |
Blood gas and hemodynamic changes induced by the treatment of pulmonary congestion with vasodilators in the acute phase of myocardial infarction.
Topics: Adult; Aged; Carbon Dioxide; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; I | 1986 |
[Comparative efficacy of the long-term use of long-acting nitroglycerin (sustak) and molsidomine after myocardial infarct complicated by heart failure].
Topics: Adult; Aged; Delayed-Action Preparations; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Mi | 1986 |
[Problems in acute therapy of coronary heart disease using drugs that reduce preload and afterload].
Topics: Coronary Disease; Heart Failure; Hemodynamics; Humans; Hypertension; Molsidomine; Nifedipine; Nitrog | 1987 |
Application of a combination of sublingually administered vasodilating drugs for rapid action on pulmonary hypertension in patients with cardiac asthma and with pulmonary oedema.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Dyspnea, Paroxysmal; Female; Heart Fai | 1987 |
[Effect of molsidomin and nifedipine on tolerance of physical exertion among rheumatic fever patients in the initial stage of heart failure].
Topics: Adult; Female; Heart Failure; Heart Valve Diseases; Humans; Male; Middle Aged; Molsidomine; Nifedipi | 1986 |
[Hemodynamic effects of molsidomine in chronic congestive heart failure].
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Catheterization; Cardiac Output; Chronic | 1986 |
[Effect of korvaton and korinfar on systemic circulation in heart failure patients].
Topics: Adult; Blood Circulation; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Middle | 1986 |
[Efficacy of corvaton in the long-term ambulatory treatment of heart failure in patients with rheumatic heart lesions].
Topics: Adult; Ambulatory Care; Cardiac Output; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Ag | 1986 |
Proceedings of the International Symposium on Molsidomine. November 5, 1983, Brussels, Belgium.
Topics: Coronary Disease; Heart Failure; Humans; Molsidomine; Oxadiazoles; Sydnones; Vasodilator Agents | 1985 |
Evaluation of the effects of molsidomine by cardiac equilibrium blood pool scintigraphy.
Topics: Adult; Aged; Cardiac Output; Heart Failure; Hemodynamics; Humans; Middle Aged; Molsidomine; Oxadiazo | 1985 |
Hemodynamic effects of molsidomine in patients with heart failure following acute myocardial infarction.
Topics: Aged; Female; Heart Failure; Hemodynamics; Humans; Male; Molsidomine; Myocardial Infarction; Oxadiaz | 1985 |
[Hemodynamic effects of molsidomine in patients with cardiac insufficiency at high altitudes].
Topics: Adolescent; Adult; Altitude; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Mi | 1985 |
Effects of molsidomine on hemodynamics and blood gases in acute myocardial infarction with left heart failure.
Topics: Aged; Carbon Dioxide; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Male; Middle Aged; Mols | 1985 |
[Classification and principles of the use of vasodilators in the treatment of left ventricular insufficiency].
Topics: Calcium Channel Blockers; Captopril; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Kinetics | 1985 |